DAWN vs. ARQT, MNKD, CSTL, LMAT, BDTX, RNA, CRNX, ADMA, ACLX, and TGTX
Should you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Arcutis Biotherapeutics (ARQT), MannKind (MNKD), Castle Biosciences (CSTL), LeMaitre Vascular (LMAT), Black Diamond Therapeutics (BDTX), Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX), ADMA Biologics (ADMA), Arcellx (ACLX), and TG Therapeutics (TGTX). These companies are all part of the "medical" sector.
Arcutis Biotherapeutics (NASDAQ:ARQT) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability.
Arcutis Biotherapeutics received 17 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. However, 64.06% of users gave Day One Biopharmaceuticals an outperform vote while only 63.74% of users gave Arcutis Biotherapeutics an outperform vote.
Day One Biopharmaceuticals has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -150.51%. Day One Biopharmaceuticals' return on equity of -50.01% beat Arcutis Biotherapeutics' return on equity.
Arcutis Biotherapeutics currently has a consensus target price of $13.33, suggesting a potential upside of 28.70%. Day One Biopharmaceuticals has a consensus target price of $35.71, suggesting a potential upside of 151.51%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than Arcutis Biotherapeutics.
In the previous week, Arcutis Biotherapeutics had 11 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 11 mentions for Arcutis Biotherapeutics and 0 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 0.97 beat Arcutis Biotherapeutics' score of 0.39 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media.
87.9% of Day One Biopharmaceuticals shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Arcutis Biotherapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.51, suggesting that its stock price is 251% less volatile than the S&P 500.
Day One Biopharmaceuticals has lower revenue, but higher earnings than Arcutis Biotherapeutics. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Day One Biopharmaceuticals beats Arcutis Biotherapeutics on 12 of the 18 factors compared between the two stocks.
Get Day One Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Day One Biopharmaceuticals Competitors List
Related Companies and Tools
